Skip to content
MetaGene Pty Ltd

Validated, Certified & Low Cost Pathology, Histology & Cancer Research Products

  • Home
  • Manufacturers
    • Applied Spectral Imaging
    • Biocare Medical
    • Empire Genomics
    • GenomeMe
    • Horizon Diagnostics
    • Interscience
    • Nordic BioSite
    • Santa Cruz Biotechnology
    • Ultivue
  • Products
    • Antibodies
    • Bag Mixer
    • Colony Counters
    • Decloaking Chamber
    • FISH Imaging and Analysis
    • FISH Probes
    • GenASIs Pathology Suite
    • Gravimetric Dilutor
    • HPV Detection Kits
    • IHC Automated Stainer
    • IHC Detection Kits
    • IHC FISH Controls
    • Peristaltic Pumps
    • PCR Reagents
    • Reference Standards
    • Slide Drying Oven
  • Company
    • About Us
    • Community
      • Triathlete Youth Sponsorships
      • Triathlete Youth Ambassador Program
    • Compliance
    • Media
    • News
      • Advanced understanding of cancer progression in circulating tumor cells through the use of multiplexed imaging technology
    • Terms and Conditions
  • Contact Us
  • Home
  • Manufacturers
    • Applied Spectral Imaging
    • Biocare Medical
    • Empire Genomics
    • GenomeMe
    • Horizon Diagnostics
    • Interscience
    • Nordic BioSite
    • Santa Cruz Biotechnology
    • Ultivue
  • Products
    • Antibodies
    • Bag Mixer
    • Colony Counters
    • Decloaking Chamber
    • FISH Imaging and Analysis
    • FISH Probes
    • GenASIs Pathology Suite
    • Gravimetric Dilutor
    • HPV Detection Kits
    • IHC Automated Stainer
    • IHC Detection Kits
    • IHC FISH Controls
    • Peristaltic Pumps
    • PCR Reagents
    • Reference Standards
    • Slide Drying Oven
  • Company
    • About Us
    • Community
      • Triathlete Youth Sponsorships
      • Triathlete Youth Ambassador Program
    • Compliance
    • Media
    • News
      • Advanced understanding of cancer progression in circulating tumor cells through the use of multiplexed imaging technology
    • Terms and Conditions
  • Contact Us

Category Archives: ASI

  • Home
  • Archive by category "ASI"

Advanced understanding of cancer progression in circulating tumor cells using multiplexed imaging technology

Applied Spectral Imaging (Israel), MetaGene and QIMR Berghofer Medical Research Institute (Australia) have developed a multiplexed fluorescent imaging system to advance the understanding of disease progression in tissue, liquid biopsy and circulating tumor cells. The system offers a cost-effective, rapid, integrated solution for up to 24-plex* MIF analysis.

Original Research Article: 

Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch
Front. Immunol., 16 June 2020 | https://doi.org/10.3389/fimmu.2020.01228

Contact us on 1800 788 498 or admin@metagene.com.au for more information on Applied Spectral Imaging technology, or visit https://spectral-imaging.com/

*Dependent on Filter and Module selection.

  • 23 Jul, 2020
  • (0) Comments
  • By metagene
  • ASI, Cancers, Digital Pathology, GenASIs System, Products
PD-L1 CELL LUNG CANCER, METAGENE, ASI

Scoring of PD-L1 in non-small cell lung cancer

Work done by Dr. Joseph, Medical Director, Department of Pathology and Laboratory Medicine, Lowell General Hospital highlights results of a comparison study between manual and computer-aided analysis for the scoring of PD-L1 in non-small cell lung cancer (NSCLC) tissue samples. Digital interpretation was found to overcome manual sampling errors and insufficient cell-count and improved the accuracy and precision of the interpretation.

READ MORE by Downloading the paper.

Download the paper here.

 

 

  • 6 Jun, 2018
  • (0) Comments
  • By metagene
  • ASI, Digital Pathology
Australia's first QDP-IHC Section, Menzies Health Centre, Griffith University, ASI, MetaGene

Introducing Australia’s first QDP-IHC Section

MetaGene and Applied Spectral Imaging (ASI) are proud to offer Australia’s first QDP-IHC Section and support the Menzies Health Institute Queensland in the creation of the country’s first Quantitative Digital Pathology – Immunohistochemistry Section (QDP-IHC). This department will utilise the GenASIs Digital Pathology platform, approved by the Federal Government Therapeutic Goods Administration (TGA) as a Class III IVD Medical Device.

“This signifies a key step in our journey towards widespread adoption of the ASI GenASIs Digital Pathology system for laboratories and patients in Australia,” MetaGene Managing Director Richard Holder said.

“GenASIs provides higher diagnostic confidence and uncompromising result standardisation, replacing previous indicative diagnosis. Having a TGA approved system at the prestigious Menzies Health Institute Queensland means clinical customers, academic pathologists and scientific researchers can now validate operational performance and benefit from a faster and more accurate means of analysis for IHC , FISH and Cytogenetic samples than ever before.

Image source: Menzies Health Institute Queensland

  • 14 Nov, 2017
  • (0) Comments
  • By metagene
  • ASI, Digital Pathology, GenASIs System
TGA Approval For New Digital Pathology System, MetaGene GenASIs System, HiPathPro, PathFusion, Applied Spectral Imaging, Cancer Diagnosis, Pathology

TGA Approval For New Digital Pathology System

https://metagene.com.au/wp-content/uploads/2017/10/MetaGene_7NewsBrisbane_26102017.mp4

 

Diagnostic digital pathology system improving the landscape of cancer diagnosis

In an Australian first, the Federal Government has granted TGA approval for a diagnostic digital pathology system set to radically improve the outlook for cancer patients through rapid and accurate diagnosis.

MetaGene has received TGA class III Medical Device certification for GenASIs – a groundbreaking diagnostic platform offering quantitative, accurate and validated analysis of patient samples in a clinical setting.

MetaGene Managing Director Richard Holder and Dr Eugen Petcu today unveiled the only fully operational GenASIs system currently in Australia, which is located at the Menzies Health Institute.

The Menzies Centre, Griffith University. Pictured: Richard Holder - MetaGene Managing Director, Dr Eugen Petcu of the Mensies Centre along with Melissa Whitehouse of MetaGene. Photography: David Clark Photography
The Menzies Centre, Griffith University. Pictured: Richard Holder – MetaGene Managing Director, Dr Eugen Petcu of the Mensies Centre along with Melissa Whitehouse of MetaGene. Photography: David Clark Photography

Mr Holder says the TGA class III certification demonstrates the system’s robust design and extensive validation as a clinical device which will alter the landscape of diagnostic technology, leading to a better outcome for patients.

“GenASIs provides higher diagnostic confidence and uncompromising result standardisation, replacing previous indicative diagnosis,” he said. “This highly anticipated system can test thousands of cells in infinitely less time with a more accurate outcome than any other system currently in the market. This not only means greater efficiency, quality control and cost savings for laboratories – it means cancer patients will have the chance to receive more personalised treatments plans based on a more accurate diagnosis.”

MetaGene is the sole Australian distributor of the GenASIs system, which is now available to hospitals and laboratories across the country.

Global leader in computer-assisted biomedical imaging, Applied Spectral Imaging (ASI), who designed the GenASIs technology, launched an upgraded GenASIs diagnostic system earlier this month at the College of American Pathologists meeting in Orlando FL.

Dr Petcu, associated with Griffith University and the Menzies Health Institute Queensland says GenASIs, which is also approved by the FDA and is currently implemented in clinical settings in the USA, Canada and Europe, is an advanced workflow solution based on revolutionary technology with industry leading applications.

“This is the beginning of an exciting new era in diagnostic technology and I am very grateful to have access to the only fully functioning GenASIs system currently in Australia for my own cancer research,” he said. “Through exceptional image quality and precise computer-assisted analysis, this technology provides uncompromising standardisation of results at the click of a button, providing a quality baseline for consistent accurate analysis of cancer cells. This counteracts the inevitable variability that comes with manual analysis.”

The Australian Bureau of Statistics estimates 17, 730 new cases of breast cancer will be diagnosed in 2017. In a study of Ki-67 – a cancer aggression marker that indicates how urgently patients require treatment – there was a 6 per cent difference between manual analysis and image analysis on the GenASIs system. The manual analysis scored lower Ki-67 results. This diagnosis may inadvertently mean those patients could be less likely to receive urgent clinical attention. After comparing the two techniques pathologists reviewed their diagnosis, changing it to reflect the GenASIs system.

Dr Petcu says the GenASIs system functions as an adjunct tool to the microscope allowing the statistical analysis of thousands of cells in relevant tumour regions to be conducted digitally.

“The system is so accurate that it can potentially prevent the need for pathologists to send samples for further testing, significantly improving the turn-around time for results,” he said. “With a faster, more accurate analysis, the patient can feel confident in their diagnosis and their treatment pathway can be tailored specifically for them.”

ABOUT ASI

ASI is a global leader in the development of biomedical imaging solutions, supporting fluorescent, Brightfield and spectral image-acquisition, for the Pathology and Cytogenetics markets.

HiPath Pro™ and PathFusion™, powered by GenASIs™, are automated imaging platforms that provide advanced diagnostic aids for pathologists, with reproducible and standardized results. ASI platforms support manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any laboratory.

ASI’s applications are FDA cleared for BandView, FISHView, CEP XY, UroVysion, ALK, HER2/neu FISH and IHC Family for: HER2, ER, PR and Ki67.

ASI serves clinical laboratories, life science companies and research institutions in over 50 countries.

 


 

DOWNLOADS

To save to your computer: right click, “Save Link As” and choose your local destination.


Media Release – GenASIs Improves Diagnosis For Cancer Patients


Quantitative Image Analysis of Ki67 Immunohistochemistry compared with manual pathologist analysis in Breast Cancer


Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry


MetaGene Presents: The Complete Digital Pathology System


Every Diagnosis Counts: HiPath Pro Advanced Digital Pathology (ASI)


Laboratory Investigation: HER2 M-Scores in Gastric/Gastroesophageal Junction Adenocarcinomas: Comparison of Digital Image Analysis and Pathologist Interpretation


Fact Sheet & Terms Used

  • 26 Oct, 2017
  • (0) Comments
  • By metagene
  • ASI, GenASIs System, Products, Suppliers
ASI announces PD-L1 Interpretation, Validated, Certified & Low Cost Pathology, Histology & Cancer Research Products

ASI announces Computer-Assisted PD-L1 Interpretation

Applied Spectral Imaging (ASI) announces that its HiPath™ IHC imaging and analysis system provides computer-assisted PD-L1 interpretation.

PD-L1 is seen as the current breakthrough therapeutic target in immuno-oncology. Following recent clinical advances, PD-L1 expression has become a key factor in determining the treatment for patients with non-small cell lung cancer (NSCLC), the most common type of cancer which accounts for 13% of the total number of cancer cases in the US. The significant success of PD-1/PD-L1 blockades in lung cancer has led to the FDA approval of revolutionary immunotherapy drugs, and PD-L1 assays are becoming standard care for all patients with a suspected lung cancer.

HiPath, ASI’s flagship system for advanced IHC imaging and analysis, is a pioneer in digital pathology solutions that support PD-L1 analysis, for research use. It determines PD-L1 protein expression by calculating the percentage of viable tumour cells showing partial or complete membrane staining, and automatically provides the tumour proportion score (TPS).

To learn more about HiPath™, contact us today.

 

  • 3 Jul, 2017
  • (0) Comments
  • By metagene
  • ASI, Products
Recent Posts
  • P40 ANTIBODY PROMOTION
  • INTERSCIENCE – FLEXIPUMP PRO $4,999*
  • Go FISH-ing with us! – 20% discount off FISH Probes
  • Discounted Decloaking Chamber™ NxGen
  • The Cleanest SOX – 25% Cheaper!
Categories
  • Antibodies
  • ASI
  • Biocare Medical
  • Cancers
  • Charity
  • COVID-19
  • Digital Pathology
  • GenASIs System
  • Horizon Discovery
  • Lockdowns
  • Nordic BioSite
  • Products
  • Sale
  • Santa Cruz Biotechnology
  • Suppliers
  • Training
GET IN TOUCH!

You can always reach us.

MetaGene prides itself on it’s exceptional customer service.

 

Hours of Operation:

8am – 8pm AEST.

 

CONTACT US

Address:

Level 34, 1 Eagle Street

Brisbane QLD 4000

Phone: Free Call 1800 788 498

Fax: 1300 307 595

Send an email:

© 2020 MetaGene Pty Ltd. All Rights Reserved.